Skip to main content

Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.

Publication ,  Journal Article
Stadtmauer, EA; Sullivan, KM; El Idrissi, M; Salaun, B; Alonso Alonso, A; Andreadis, C; Anttila, V-J; Bloor, AJ; Broady, R; Cellini, C; Eom, H ...
Published in: Hum Vaccin Immunother
November 2, 2021

Immunocompromised individuals, particularly autologous hematopoietic stem cell transplant (auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth description of humoral and cell-mediated immune (CMI) responses by age (protocol-defined) or underlying disease (post-hoc) as well as efficacy by underlying disease (post-hoc) of the adjuvanted recombinant zoster vaccine (RZV) in a randomized observer-blind phase III trial (ZOE-HSCT, NCT01610414). 1846 adult auHSCT recipients were randomized to receive a first dose of either RZV or placebo 50-70 days post-auHSCT, followed by the second dose at 1-2 months (M) later. In cohorts of 114-1721 participants, at 1 M post-second vaccine dose: Anti-gE antibody geometric mean concentrations (GMCs) and median gE-specific CD4[2+] T-cell frequencies (CD4 T cells expressing ≥2 of four assessed activation markers) were similar between 18-49 and ≥50-year-olds. Despite lower anti-gE antibody GMCs in non-Hodgkin B-cell lymphoma (NHBCL) patients, CD4[2+] T-cell frequencies were similar between NHBCL and other underlying diseases. The proportion of polyfunctional CD4 T cells increased over time, accounting for 79.6% of gE-specific CD4 T cells at 24 M post-dose two. Vaccine efficacy against HZ ranged between 42.5% and 82.5% across underlying diseases and was statistically significant in NHBCL and multiple myeloma patients. In conclusion, two RZV doses administered early post-auHSCT induced robust, persistent, and polyfunctional gE-specific immune responses. Efficacy against HZ was also high in NHBCL patients despite the lower humoral response.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Hum Vaccin Immunother

DOI

EISSN

2164-554X

Publication Date

November 2, 2021

Volume

17

Issue

11

Start / End Page

4144 / 4154

Location

United States

Related Subject Headings

  • Virology
  • Vaccine Efficacy
  • Immunity, Cellular
  • Humans
  • Herpesvirus 3, Human
  • Herpes Zoster Vaccine
  • Herpes Zoster
  • Hematopoietic Stem Cell Transplantation
  • 3207 Medical microbiology
  • 3206 Medical biotechnology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stadtmauer, E. A., Sullivan, K. M., El Idrissi, M., Salaun, B., Alonso Alonso, A., Andreadis, C., … Bastidas, A. (2021). Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. Hum Vaccin Immunother, 17(11), 4144–4154. https://doi.org/10.1080/21645515.2021.1953346
Stadtmauer, Edward A., Keith M. Sullivan, Mohamed El Idrissi, Bruno Salaun, Aránzazu Alonso Alonso, Charalambos Andreadis, Veli-Jukka Anttila, et al. “Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.Hum Vaccin Immunother 17, no. 11 (November 2, 2021): 4144–54. https://doi.org/10.1080/21645515.2021.1953346.
Stadtmauer EA, Sullivan KM, El Idrissi M, Salaun B, Alonso Alonso A, Andreadis C, et al. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. Hum Vaccin Immunother. 2021 Nov 2;17(11):4144–54.
Stadtmauer, Edward A., et al. “Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.Hum Vaccin Immunother, vol. 17, no. 11, Nov. 2021, pp. 4144–54. Pubmed, doi:10.1080/21645515.2021.1953346.
Stadtmauer EA, Sullivan KM, El Idrissi M, Salaun B, Alonso Alonso A, Andreadis C, Anttila V-J, Bloor AJ, Broady R, Cellini C, Cuneo A, Dagnew AF, Di Paolo E, Eom H, González-Rodríguez AP, Grigg A, Guenther A, Heineman TC, Jarque I, Kwak J-Y, Lucchesi A, Oostvogels L, Polo Zarzuela M, Schuind AE, Shea TC, Sinisalo UM, Vural F, Yáñez San Segundo L, Zachée P, Bastidas A. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. Hum Vaccin Immunother. 2021 Nov 2;17(11):4144–4154.

Published In

Hum Vaccin Immunother

DOI

EISSN

2164-554X

Publication Date

November 2, 2021

Volume

17

Issue

11

Start / End Page

4144 / 4154

Location

United States

Related Subject Headings

  • Virology
  • Vaccine Efficacy
  • Immunity, Cellular
  • Humans
  • Herpesvirus 3, Human
  • Herpes Zoster Vaccine
  • Herpes Zoster
  • Hematopoietic Stem Cell Transplantation
  • 3207 Medical microbiology
  • 3206 Medical biotechnology